What's new? Log in Free sign up

Horizon Therapeutics (HZNP) News and press releases

Company Profile

News

From Benzinga Pro

Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline

Biotech, Earnings, Large Cap, News, Health Care, General

Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts

Analyst Color, Biotech, News, Penny Stocks, Health Care, Price Target, Reiteration, Analyst Ratings, General

Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder

Biotech, News, Health Care, General

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep For The Treatment Of Sjögren's Syndrome Meets Primary Endpoint In The Second Study Population

Biotech, News, FDA, General

- Trial also met primary endpoint in first study population as announced September 2022 – - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations -

$1000 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth This Much Today

Earnings, News, Dividends

Horizon Therapeutics plc Announces First Patient Enrolled In Phase 2 Trial Evaluating Daxdilimab For The Treatment Of Discoid Lupus Erythematosus

Biotech, News, FDA, General

Horizon Therapeutics plc (NASDAQ:HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially

5 Most Expensive Health Care Stocks You Should Worry About

News, Short Ideas, Health Care, Small Cap, Pre-Market Outlook, Markets, Trading Ideas, General

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today

Earnings, News, Dividends

A Bullish Sign Appears On Horizon Therapeutics's Chart

Markets, Movers, Trading Ideas

Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector

News, Short Ideas, Pre-Market Outlook, Markets, Trading Ideas

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.

Analyzing Horizon Therapeutics's Short Interest

Short Sellers, Short Ideas, Trading Ideas

Horizon Therapeutics's (NASDAQ:HZNP) short percent of float has fallen 7.07% since its last report. The company recently reported that it has 6.49 million shares sold short, which is 2.89% of all regular shares that are available for trading.

UPLIZNA Approved In Brazil For The Treatment Of Neuromyelitis Optica Spectrum Disorder

Biotech, News, Global, General

-- First and only anti-CD19 B-cell-depleting monotherapy for the treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) -- -- NMOSD is a devastating rare

Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?

News, Short Ideas, Markets, Trading Ideas

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI above or near 70.

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

BMO Capital Downgrades Horizon Therapeutics to Market Perform

News, Downgrades, Analyst Ratings

BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.

Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...'

M&A, News, Small Cap, Markets

Prominent market commentator Jim Cramer said three corporate deals announced on Monday aided the rally seen at the beginning of the week,

Guggenheim Downgrades Horizon Therapeutics to Neutral, Raises Price Target to $116.5

News, Downgrades, Price Target, Analyst Ratings

Guggenheim analyst Yatin Suneja downgrades Horizon Therapeutics (NASDAQ:HZNP) from Buy to Neutral and raises the price target from $98 to $116.5.

SVB Leerink Downgrades Horizon Therapeutics to Market Perform, Raises Price Target to $116.5

News, Downgrades, Price Target, Analyst Ratings

SVB Leerink analyst David Risinger downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform and raises the price target from $88 to $116.5.

Wells Fargo Downgrades Horizon Therapeutics to Equal-Weight, Lowers Price Target to $116.5

News, Downgrades, Price Target, Analyst Ratings

Wells Fargo analyst Derek Archila downgrades Horizon Therapeutics (NASDAQ:HZNP) from Overweight to Equal-Weight and lowers the price target from $118 to $116.5.

Press releases

From Benzinga Pro

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023

Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets. In light of

Rule 15 (c) Announcement – Horizon Therapeutics plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, COUP, MLVF, TCFC

NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) to

Rule 17 (b) Announcement – Horizon Therapeutics plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION Horizon

Rule 17 (a) Announcement – Horizon Therapeutics plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION Horizon

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, AGFS, SAL, HZNP

News, Legal, Press Releases

NEW YORK, Jan. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

SHAREHOLDER ALERT: Weiss Law Reminds SAL, SHBI, HZNP, and IMRA Shareholders About Its Ongoing Investigations

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAL, HZNP, COUP, TCFC

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNBE, AGFS, HZNP, QUMU

NEW YORK, NY / ACCESSWIRE / January 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

Rule 2.12 Announcement – Horizon Therapeutics plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAL, HZNP, TIG, QUMU

News, Legal, Press Releases

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

SHAREHOLDER ALERT: Weiss Law Reminds BRBW, MPB, COUP, and HZNP Shareholders About Its Ongoing Investigations

Small Cap, Press Releases

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, BNFT, HZNP

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Horizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, MLVF, TCFC

News, Legal, Press Releases

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Horizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Horizon Therapeutics plc (NASDAQ:HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Horizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, SESN

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties